U.S., July 12 -- ClinicalTrials.gov registry received information related to the study (NCT07059650) titled 'DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)' on June 16.
Brief Summary: This study will treat patients with diffuse large B-cell lymphoma (DLBCL). It will assess the anti-tumor efficacy and safety of DZD8586 combination therapy by using objective response rate and the incidence and severity of adverse events. It will also measure the levels of DZD8586 in the body when combined with immunochemotherapy regimens.
Study Start Date: Sept., 2025
Study Type: INTERVENTIONAL
Condition:
Diffuse Large B-Cell Lymphoma
Intervention:
DRUG: DZD8586+R-CHOP
DZD8586 at the protocol defined dose level...